LifeTech Scientific Corporation (LFTSF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LifeTech Scientific Corporation (LFTSF) trades at $0.20 with AI Score 63/100 (Grade B+). LifeTech Scientific Corporation develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases, operating globally across structural heart, peripheral vascular, and cardiac pacing segments. Market cap: $858.15M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for LFTSF: LFTSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LFTSF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LFTSF: 4/4 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →LifeTech Scientific Corporation (LFTSF) Healthcare & Pipeline Overview
LifeTech Scientific Corporation is a Shenzhen-based developer and manufacturer of interventional medical devices for cardiovascular and peripheral vascular diseases. The company offers a diverse product portfolio, including LAA closure systems, occluders, stent grafts, and pacemakers, serving global markets across structural heart, peripheral vascular, and cardiac pacing segments.
What Is the Investment Thesis for LFTSF?
LifeTech Scientific Corporation presents a focused investment profile centered on its specialization in interventional medical devices for cardiovascular and peripheral vascular diseases, a sector driven by an aging global population and increasing disease prevalence. The company's robust product portfolio, encompassing LAA closure systems, occluders, stent grafts, and pacemakers, positions it to capitalize on the growing demand for minimally invasive procedures. Financially, LifeTech demonstrates strong product profitability with a Gross Margin of 74.4% and a Profit Margin of 10.8%, alongside substantial Free Cash Flow of $1.02 billion, indicating efficient operations and cash generation. Its conservative capital structure is reflected by a Debt-to-Equity ratio of 0.23. While the Return on Equity stands at 3.2%, the company's global operational footprint across Mainland China, India, Europe, and other regions provides diverse market access and potential for future expansion. Continued investment in biomedical R&D and strategic market penetration in emerging economies are key catalysts for sustained growth, leveraging its established device platforms and technical expertise.
Based on FMP financials and quantitative analysis
LFTSF Key Highlights
- Market Capitalization: $1.03 billion, indicating its scale within the specialized medical device sector.
- Gross Margin: 74.4%, reflecting strong product profitability and efficient manufacturing processes.
- Profit Margin: 10.8%, demonstrating effective cost management and operational efficiency.
- Free Cash Flow: $1.02 billion, highlighting robust cash generation capabilities from its core operations.
- Debt-to-Equity Ratio: 0.23, suggesting a conservative capital structure and prudent financial management.
Who Are LFTSF's Competitors?
LFTSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TSUSF Tsuruha Holdings Inc. | $17.25 | +0.00% | $4.20B | 49 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| QIPT Quipt Home Medical Corp. | $3.65 | +0.00% | $162.30M | 63 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.36M | 64 |
| TLSI TriSalus Life Sciences, Inc. | $4.31 | -8.10% | $163.39M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LFTSF's Key Strengths?
- Specialized and diverse product portfolio in interventional medical devices for cardiovascular and peripheral vascular diseases.
- Global operational presence across multiple continents, including significant emerging markets.
- Strong gross margin of 74.4% indicates efficient production and pricing power.
- Robust Free Cash Flow of $1.02 billion, demonstrating strong financial health and liquidity.
- Conservative capital structure with a Debt-to-Equity ratio of 0.23.
What Are LFTSF's Weaknesses?
- Relatively low Return on Equity (ROE) of 3.2%, suggesting potential for improved capital efficiency.
- Reliance on specific medical device markets, which can be subject to intense competition and regulatory changes.
- Disclosure status on the OTC market is 'Unknown', potentially limiting investor information.
- Specific details regarding CEO's background and track record are not publicly provided.
What Could Drive LFTSF Stock Higher?
- Global expansion into new geographic markets, particularly in emerging economies, is expected to drive increased sales and market share for its interventional medical devices.
- Continuous research and development efforts leading to the launch of new products or significant enhancements to existing device lines, potentially expanding addressable markets and improving competitive positioning.
- Increasing adoption rates of minimally invasive cardiovascular and peripheral vascular procedures worldwide, directly benefiting demand for LifeTech Scientific Corporation's specialized device portfolio.
- Potential for new regulatory approvals for key products in major international markets, which could unlock significant revenue opportunities and broaden market access.
- Strategic partnerships with healthcare providers or distribution networks that could accelerate market penetration and product uptake in key regions.
What Are the Key Risks for LFTSF?
- Intense competition within the highly innovative and regulated medical device industry, potentially impacting market share and pricing power.
- Adverse regulatory changes or delays in obtaining product approvals in critical markets, which could hinder product launches and revenue growth.
- Risks associated with product liability claims, recalls, or intellectual property infringement, which could lead to significant financial and reputational damage.
- Fluctuations in global economic conditions, healthcare spending policies, and reimbursement trends that could negatively affect demand for medical devices.
- Challenges inherent in operating on the OTC market, including lower liquidity, wider bid-ask spreads, and the 'Unknown' disclosure status, which may deter institutional investors.
What Are the Growth Opportunities for LFTSF?
- Expansion in Emerging Markets: LifeTech Scientific Corporation has established operations in Mainland China, India, rest of Asia, South America, and Africa. These regions represent significant growth opportunities due to their large populations, increasing healthcare expenditure, and rising awareness of cardiovascular and peripheral vascular diseases. As healthcare infrastructure improves and access to advanced medical treatments expands, the demand for interventional devices is expected to surge, providing LifeTech with a substantial addressable market for its specialized products over the next decade.
- Product Portfolio Diversification and Innovation: The company's engagement in biomedical research and development is a crucial growth driver. Continuous innovation in existing product lines, such as LAmbre left atrial appendage closure systems and Ankura stent grafts, along with the introduction of new interventional devices, can capture additional market share. Investing in R&D to develop next-generation technologies or expand into adjacent therapeutic areas within cardiovascular health could unlock new revenue streams and strengthen its competitive position in the long term, potentially over the next five to ten years.
- Increased Adoption of Minimally Invasive Procedures: There is a global trend towards minimally invasive surgical techniques due to benefits like reduced patient recovery times, lower hospital stays, and decreased complication rates. LifeTech's product suite, which includes various occluders, stent grafts, and delivery systems, is specifically designed for such procedures. As healthcare systems worldwide continue to prioritize patient outcomes and cost-effectiveness, the adoption of these advanced interventional devices is projected to grow steadily, offering a sustained growth trajectory for LifeTech over the coming years.
- Addressing the Aging Global Population: The demographic shift towards an older global population inherently leads to an increased incidence of age-related cardiovascular and peripheral vascular diseases. This demographic trend creates a foundational and continuously expanding demand for LifeTech's specialized medical devices, including pacemakers and aneurysm stent grafts. As life expectancies rise, the need for effective, long-term solutions for these conditions will intensify, providing a robust and enduring market for the company's products well into the foreseeable future.
- Strategic Partnerships and Market Penetration: Forming strategic alliances with leading hospitals, research institutions, or distribution networks in key international markets can significantly accelerate LifeTech's market penetration. Such partnerships can facilitate clinical trials, enhance product visibility, and streamline regulatory approvals, especially in regions like Europe and South America where the company already has a presence. This approach can lead to faster market adoption and increased sales volumes for its interventional devices, with potential impacts visible within a three to five-year timeframe.
What Opportunities Does LFTSF Have?
- Expanding global healthcare markets, particularly in emerging economies with rising demand for advanced medical treatments.
- Continuous technological advancements in medical devices, allowing for new product development and market expansion.
- Increasing adoption of minimally invasive procedures, aligning with the company's core product offerings.
- Strategic partnerships or acquisitions to enhance market reach or expand product capabilities.
- Addressing the growing demand for cardiovascular and peripheral vascular treatments driven by an aging global population.
What Threats Does LFTSF Face?
- Intense competition within the highly innovative and regulated medical device industry.
- Potential for adverse regulatory changes or delays in product approvals in key markets.
- Risks associated with product liability claims, recalls, or intellectual property disputes.
- Fluctuations in global economic conditions and healthcare spending policies.
- Challenges inherent in operating on the OTC market, including potential for lower liquidity and price volatility.
What Are LFTSF's Competitive Advantages?
- Specialized product portfolio in complex interventional cardiology and peripheral vascular devices, requiring significant R&D and regulatory expertise.
- Global operational footprint across diverse and growing healthcare markets, including Asia, Europe, and South America.
- Ongoing biomedical research and development capabilities, fostering innovation and product pipeline expansion.
- Established regulatory approvals and clinical data for specific devices, creating barriers to entry for competitors.
- High gross margin of 74.4% suggests strong pricing power and cost efficiency in its niche market.
What Does LFTSF Do?
LifeTech Scientific Corporation, founded in 1999 and headquartered in Shenzhen, the People's Republic of China, operates as an investment holding company primarily focused on the development, manufacturing, and trading of interventional medical devices. The company's core mission addresses cardiovascular and peripheral vascular diseases and disorders, providing critical solutions in a rapidly evolving healthcare landscape. Its operational structure is segmented into Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business, reflecting a comprehensive approach to vascular health. The extensive product portfolio includes advanced LAmbre left atrial appendage closure systems, various CeraFlex, Cera, Heart, and Konara-MF VSD occluders for structural heart defects, and Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems. Complementing these primary devices are essential delivery systems like Fustar steerable and SteerEase introducers, Aegisy vena cava filters, Cera vascular plug systems, AcuMark sizing balloons, LawMax dilators, and SeQure snare systems, alongside pacemakers. Beyond device manufacturing, LifeTech Scientific Corporation is actively involved in biomedical research and development, manufacturing and trading of materials for hemp, staff training, internal personnel management, information consulting for investors, and a range of technical, consulting, and technology services. With a workforce of 1395 employees, the company has established a significant international presence, conducting operations in Mainland China, India, the rest of Asia, Europe, South America, and Africa, underscoring its commitment to global healthcare markets.
What Products and Services Does LFTSF Offer?
- Develops and manufactures interventional medical devices for cardiovascular and peripheral vascular diseases.
- Offers LAmbre left atrial appendage closure systems for structural heart conditions.
- Produces a range of occluders, including CeraFlex, Cera, Heart, and Konara-MF VSD occluders.
- Provides Ankura thoracic and abdominal aortic aneurysm stent graft systems.
- Manufactures delivery systems such as Fustar steerable and SteerEase introducers.
- Supplies pacemakers for cardiac rhythm management.
- Engages in biomedical research and development to innovate new medical technologies.
- Operates globally, with a presence in Mainland China, India, Asia, Europe, South America, and Africa.
How Does LFTSF Make Money?
- Develops and manufactures a proprietary portfolio of interventional medical devices targeting cardiovascular and peripheral vascular diseases.
- Generates revenue primarily through the direct sale and distribution of these specialized medical devices to hospitals, clinics, and healthcare providers globally.
- Operates across three distinct business segments: Structural Heart Diseases, Peripheral Vascular Diseases, and Cardiac Pacing and Electrophysiology.
- Invests in biomedical research and development to innovate new products and enhance existing ones, securing future revenue streams.
- Provides technical, consulting, and technology services related to its medical device expertise.
What Industry Does LFTSF Operate In?
LifeTech Scientific Corporation operates within the highly specialized and competitive Medical Devices industry, specifically targeting the cardiovascular and peripheral vascular disease segments. This sector is characterized by continuous innovation, stringent regulatory requirements, and a growing global demand driven by an aging population and increasing prevalence of chronic diseases. Market trends indicate a strong shift towards minimally invasive interventional procedures, which aligns directly with LifeTech's core product offerings such as occluders, stent grafts, and LAA closure systems. The competitive landscape includes both large multinational corporations and specialized regional players. LifeTech Scientific Corporation distinguishes itself through its focused product development and manufacturing capabilities, coupled with an expanding international presence across Asia, Europe, South America, and Africa. Its position as a developer and trader of interventional devices allows it to address critical needs in a market where technological advancement and clinical efficacy are paramount.
Who Are LFTSF's Key Customers?
- Hospitals and medical centers requiring specialized interventional devices.
- Cardiologists, interventional radiologists, and vascular surgeons performing complex procedures.
- Healthcare systems and purchasing organizations seeking advanced medical technologies.
- Patients suffering from cardiovascular and peripheral vascular diseases who benefit from minimally invasive treatments.
FY2026 estForward Outlook
Wall Street analysts project LifeTech Scientific Corporation revenue of about $1.50B for fiscal 2026, with EPS near $0.08.
LFTSF Valuation & Market Position
With a $858.15M market cap, LifeTech Scientific Corporation sits in the small-cap segment of the market. Relative to its peer group, LFTSF's quantitative score of 63/100 is roughly in line with the peer average of 67/100.
ROE 4%Key Financial Metrics
Return on equity for LifeTech Scientific Corporation stands at 4.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.9%, showing how much profit it generates from its asset base. LFTSF trades at a trailing price-to-earnings ratio of 37.35, above the Healthcare sector average of ~23x. Its free cash flow yield is 9.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
LifeTech Scientific Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.22 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
LifeTech Scientific Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Shenzhen, CN. The company is led by CEO Yuehui Xie. LFTSF has traded publicly since 2021.
LFTSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized and diverse product portfolio in interventional medical devices for cardiovascular and peripheral vascular diseases.
- Global operational presence across multiple continents, including significant emerging markets.
- Strong gross margin of 74.4% indicates efficient production and pricing power.
- Robust Free Cash Flow of $1.02 billion, demonstrating strong financial health and liquidity.
Bear Case
- Relatively low Return on Equity (ROE) of 3.2%, suggesting potential for improved capital efficiency.
- Reliance on specific medical device markets, which can be subject to intense competition and regulatory changes.
- Disclosure status on the OTC market is 'Unknown', potentially limiting investor information.
- Specific details regarding CEO's background and track record are not publicly provided.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
LFTSF Latest News
No recent news available for LFTSF.
LFTSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LFTSF.
Price Targets
Wall Street price target analysis for LFTSF.
LFTSF MoonshotScore
What does this score mean?
The MoonshotScore rates LFTSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yuehui Xie
Unknown
Specific details regarding Yuehui Xie's extensive career history, educational background, and previous roles prior to their current position at LifeTech Scientific Corporation are not explicitly provided in the available data. However, as a key leader, they are responsible for managing the company's workforce of 1395 employees, overseeing operations across its diverse segments in interventional medical devices.
Track Record: Key achievements and strategic decisions under Yuehui Xie's leadership are not detailed in the provided information. Their role involves guiding LifeTech Scientific Corporation's strategic direction and operational execution as it develops, manufactures, and trades interventional medical devices globally, impacting the company's overall performance and market presence.
LFTSF OTC Market Information
LifeTech Scientific Corporation trades on the 'OTC Other' tier of the OTC market. This tier typically includes companies that do not meet the listing requirements for higher tiers like OTCQX or OTCQB, or choose not to provide extensive disclosure. Unlike major exchanges such as NYSE or NASDAQ, which have strict listing standards regarding financial health, corporate governance, and minimum share prices, the 'OTC Other' tier has fewer regulatory requirements, which can affect transparency and investor confidence. It generally represents companies that are current in their reporting to a U.S. regulator or a foreign regulator, or are banks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower Liquidity: Shares may be difficult to buy or sell quickly without affecting the price.
- Limited Information: 'Unknown' disclosure status means less financial and operational transparency.
- Price Volatility: Shares can experience significant and unpredictable price swings due to low trading volume.
- Regulatory Oversight: Less stringent regulatory oversight compared to major exchanges.
- Fraud Risk: Increased potential for market manipulation or fraudulent activities due to less transparency.
- Review any available financial statements and annual reports, even if disclosure status is unknown.
- Assess the company's business operations, product pipeline, and market position thoroughly.
- Research the management team's background and track record, if information is available.
- Examine trading volume and bid-ask spreads to understand liquidity characteristics.
- Investigate any regulatory filings or news releases from the company or relevant authorities.
- Evaluate the company's global presence and market penetration in its target regions.
- Understand the specific risks associated with the 'OTC Other' tier and the 'Unknown' disclosure status.
- Established Founding Year: Founded in 1999, indicating a long operational history.
- Specific Product Portfolio: Develops and manufactures tangible interventional medical devices.
- Global Operations: Presence in Mainland China, India, Asia, Europe, South America, and Africa.
- Significant Employee Base: Employs 1395 individuals, suggesting a substantial operational scale.
- Market Capitalization: A market cap of $858.15M, indicating a considerable valuation for an OTC-traded company.
What Investors Ask About LifeTech Scientific Corporation (LFTSF) — Healthcare
What does LifeTech Scientific Corporation do?
LifeTech Scientific Corporation is a Shenzhen-based investment holding company specializing in the development, manufacturing, and trading of interventional medical devices. The company primarily targets cardiovascular and peripheral vascular diseases, offering a comprehensive product range that includes LAmbre left atrial appendage closure systems, various VSD occluders, Ankura thoracic and abdominal aortic aneurysm stent graft systems, and pacemakers. Beyond device production, LifeTech engages in biomedical R&D and provides related technical and consulting services. With operations spanning Mainland China, India, other parts of Asia, Europe, South America, and Africa, the company aims to address critical healthcare needs globally.
How does LifeTech Scientific Corporation manage product innovation and market competition in the medical device sector?
LifeTech Scientific Corporation manages product innovation through continuous biomedical research and development, which is a core part of its operations. This commitment allows the company to develop advanced interventional medical devices and enhance its existing product lines, such as LAA closure systems and stent grafts, to meet evolving clinical needs. To navigate market competition, LifeTech leverages its specialized product portfolio and global operational footprint. By focusing on specific segments within cardiovascular and peripheral vascular diseases and expanding into diverse international markets, the company aims to differentiate its offerings and capture market share against both large multinational corporations and regional players, supported by its strong gross margin.
What are the primary geographic markets for LifeTech Scientific Corporation's medical devices?
LifeTech Scientific Corporation has established a significant international presence, with its primary geographic markets extending across multiple continents. The company's operations are firmly rooted in Mainland China, its home market. Beyond China, LifeTech has a strong footprint in India and the broader Asian region. It also extends its reach into Europe, South America, and Africa. This diverse geographic spread allows LifeTech to tap into various healthcare economies and address the global burden of cardiovascular and peripheral vascular diseases, capitalizing on different market dynamics and growth opportunities worldwide for its interventional medical devices.
What are the implications of LifeTech Scientific Corporation trading on the OTC market?
Trading on the OTC market, specifically in the 'OTC Other' tier, carries several implications for LifeTech Scientific Corporation and its investors. This tier typically has fewer regulatory requirements compared to major exchanges, which can result in less public disclosure and transparency, as indicated by the 'Unknown' disclosure status. Investors may face challenges in accessing comprehensive financial and operational information. Furthermore, OTC stocks often experience lower liquidity, meaning shares can be harder to buy or sell quickly without impacting the price, and bid-ask spreads can be wider. This environment can lead to increased price volatility and potentially higher transaction costs, requiring investors to conduct thorough due diligence.
What are the key factors to evaluate for LFTSF?
LifeTech Scientific Corporation (LFTSF) holds an AI score of 63/100 (moderate). Not financial advice.
How frequently does LFTSF data refresh on this page?
LFTSF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LFTSF's recent stock price performance?
LifeTech Scientific Corporation (LFTSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized and diverse product portfolio in interventional medical devices for cardiovascular and peripheral vascular diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LFTSF overvalued or undervalued right now?
Valuing LifeTech Scientific Corporation (LFTSF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Competitor 'TSUSF' (Tsuruha Holdings Inc.) is a drug store chain, which appears to be a data discrepancy given LifeTech Scientific Corporation's medical device business. Information used as provided.